Crohn's Disease Clinical Trials in Providence, Rhode Island

9 studies are recruiting for crohn's disease in Providence, Rhode Island right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

   Crohn's disease (CD) and Ulcerative colitis (UC) are 2 types of inflammatory bowel diseases which cause long-lasting, severe inflammation (redness, swelling) in the digestive tract. CD can affect any part of the digestive tract causing many different symptoms including belly pain, diarrhea, tiredne…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   University Gastroenterology - Providence - Staniford Street /ID# 280919, Providence, Rhode Island

   Locations

   36 in total

   Run by

   AbbVie

   See if you can join NCT07697456 on ClinicalTrials.gov

2. A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

   The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinica…

   Stage

   Phase 3

   Ages

   16 to 80

   Site

   University Gastroenterology - Providence - West River Street ( Site 5057), Providence, Rhode Island

   Locations

   499 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06430801 on ClinicalTrials.gov

3. A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

   Ulcerative Colitis (UC) and Crohn's Disease (CD) are long-term conditions in the gut that can cause diarrhea, swelling (inflammation), bleeding from the anus, and belly pain. The main aim of this study is to check for how many participants with UC and CD signs and symptoms disappear after 3.5 month…

   Stage

   Phase 4

   Ages

   18 to 80

   Site

   University Gastroenterology, Providence, Rhode Island

   Locations

   101 in total

   Run by

   Takeda

   See if you can join NCT06581328 on ClinicalTrials.gov

4. A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

   The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab (VDZ) together with ustekinumab (UST) in adults with moderate to severe Crohn's Disease, and the effect of treatment with vedolizumab alone, after the dual …

   Stage

   Phase 4

   Ages

   18 to 70

   Site

   University Gastroenterology, Providence, Rhode Island

   Locations

   48 in total

   Run by

   Takeda

   See if you can join NCT06045754 on ClinicalTrials.gov

5. Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

   The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight. The maximum duration of this study is up to 6…

   Stage

   Phase 3

   Ages

   18 to 70

   Site

   University Gastroenterology, Providence, Rhode Island

   Locations

   183 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06937099 on ClinicalTrials.gov

6. A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

   Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate the efficacy and safety of TAK-279 versus placebo in participants with moderately to severely active Crohn's disease (CD). The main aim of this study i…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   University Gastroenterology Providence, Providence, Rhode Island

   Locations

   190 in total

   Run by

   Takeda

   See if you can join NCT06233461 on ClinicalTrials.gov

7. An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

   This is a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 3 induction study, comprised of 3 sub-studies, to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active CD. Study details include: The study duration may be up to 35 …

   Stage

   Phase 3

   Ages

   16 to 80

   Site

   University Gastroenterology - GI Alliance - Site Number: 8400103, Providence, Rhode Island

   Locations

   301 in total

   Run by

   Sanofi

   See if you can join NCT07184931 on ClinicalTrials.gov

8. A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

   The study is an extension of two parent studies (MLN0002-3024 [NCT04779307] and MLN0002-3025 [NCT04779320]). Participants must have participated in one of the previous studies. The purpose of this study is to collect the long-term safety of vedolizumab in children with UC or CD.

   Stage

   Phase 3

   Ages

   2 and older

   Site

   Hasbro Children's Hospital - PIN, Providence, Rhode Island

   Locations

   98 in total

   Run by

   Takeda

   See if you can join NCT05442567 on ClinicalTrials.gov

9. A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

   This is a Phase 2, multicenter, platform study in adult participants with IBD (moderately to severely active Crohn's Disease or Ulcerative Colitis). The primary goal of this study is to assess the safety and efficacy of multiple investigational drugs.

   Stage

   Phase 2

   Ages

   18 to 80

   Site

   Mirador Therapeutics Selected Site, Providence, Rhode Island

   Locations

   66 in total

   Run by

   Mirador Therapeutics, Inc.

   See if you can join NCT07113522 on ClinicalTrials.gov